Kineta (KA) Reports Q1, Provides Update on Phase 1/2 VISTA-101 Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St set for mixed open ahead of SK Hynix listing; Middle East in focus
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
May 15, 2024 4:01 PM EDTPartial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level
Cleared fifth of six monotherapy cohorts and second of four combination cohorts
Kineta is actively exploring strategic alternatives to maximize value for all stakeholders
Received $500,000 investment from an existing investor
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq:... More
